Arcutis logo.png
Arcutis Announces Additions to its Investor Relations and Communications Team
August 02, 2021 16:05 ET | Arcutis Biotherapeutics, Inc.
Eric McIntyre joins as Head of Investor RelationsAmanda Sheldon joins as Head of Corporate Communications WESTLAKE VILLAGE, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics,...
Arcutis logo.png
Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate Psoriasis
July 21, 2021 08:00 ET | Arcutis Biotherapeutics, Inc.
The majority of patients with psoriasis have mild or moderate levels of diseaseThe new method, PASI-high discrimination (PASI-HD), is designed for use in clinical trials evaluating novel topical...
Arcutis logo.png
Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis
July 12, 2021 08:00 ET | Arcutis Biotherapeutics, Inc.
Topical roflumilast potential “Best-in-Class” topical PDE4 inhibitorSeborrheic dermatitis affects 10 million patients in the U.S.Potential first new topical treatment for seborrheic dermatitis in...
Arcutis logo.png
Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo
July 01, 2021 06:00 ET | Arcutis Biotherapeutics, Inc.
Formulation-related observations from ARQ-252 trial in chronic hand eczema informed early termination of Phase 2a ARQ-252 trial in vitiligoCompany progressing new formulation with goal of greater drug...
Arcutis logo.png
Greg Sukay Joins Arcutis as Vice President of Manufacturing and Process Technologies
June 23, 2021 08:00 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...
Arcutis logo.png
Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors
June 09, 2021 16:01 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...
Arcutis logo.png
Rajvir Madan Joins Arcutis as Chief Digital and Information Officer
June 01, 2021 07:30 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...
Arcutis logo.png
Arcutis Biotherapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
November 11, 2020 16:05 ET | Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...